Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Melanoma Adverse Event E1609 NCT01274338 - Adverse Event Melanoma (CTCAE v4) - Arm A NCT01274338

- 21/04/2015 - 1 Formulário, 5 Grupos de itens, 24 Elementos de dados, 1 Idioma

Grupos de itens: Header Module, ON TREATMENT, Adverse Event, Adverse event hematologic or metabolic, Other Adverse Events

E1609 Adverse Event Form (CTCAE v4) - Arm A Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery NCT01274338 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=97ED76E3-6554-CD9F-E040-BB89AD430E2E

Melanoma Adverse Event E1609 NCT01274338 - Adverse Event Melanoma (CTCAE v4) Arm B NCT01274338

- 21/04/2015 - 1 Formulário, 5 Grupos de itens, 24 Elementos de dados, 1 Idioma

Grupos de itens: Header Module, ON TREATMENT, Adverse Event, Adverse event hematologic or metabolic, Other Adverse Events

E1609 Adverse Event Form (CTCAE v4) - Arm B Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery NCT01274338 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=97EE0CB8-33DE-A52C-E040-BB89AD436A24

Toxicity - Melanoma-Adverse Event Form - 2020197v2.31 - Melanoma-Adverse Event Form

- 08/01/2015 - 1 Formulário, 5 Grupos de itens, 26 Elementos de dados, 1 Idioma

Grupos de itens: CRF Header, MELANOMA: FORM ADMINISTRATION, MELANOMA: ADVERSE EVENTS, MELANOMA: VACCINE INJECTION SITE REACTON, Comments

Melanoma-Adverse Event Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99CD59C5-A99A-3FA4-E034-080020C9C0E0

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Non-Serious Adverse Events; Study Conclusion (Report Final and Annex Report 2 Final)

- 02/11/2020 - 1 Formulário, 7 Grupos de itens, 31 Elementos de dados, 1 Idioma

Grupos de itens: Administrative, Non-Serious Adverse Event, Non-Serious Adverse Event , Death Form, Study Conclusion - Pregnancy Information, Study Conclusion, Study Conclusion - Investigator's Siganture

Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

E2603 Adverse Event Form - (CTCAE v3) (6/05) NCT00110019

- 08/07/2015 - 1 Formulário, 11 Grupos de itens, 35 Elementos de dados, 1 Idioma

Grupos de itens: ECOG clinical trial administrative data, Patient demographics, Data amendment, ON TREATMENT, OFF TREATMENT, Adverse Event Current Assessment, BLOOD/BONE MARROW/METABOLIC/LABORATORY, NON-HEMATOLOGIC, II. INFECTIONS, Other Adverse Events, Comments

E2603 Adverse Event Form - (CTCAE v3) (6/05) NCT00110019 Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FA0E0E3F-734F-5246-E034-0003BA3F9857

E2603 Adverse Event Form - (CTCAE v3) NCT00110019

- 08/07/2015 - 1 Formulário, 9 Grupos de itens, 32 Elementos de dados, 1 Idioma

Grupos de itens: Header, Patient demographics, Data amendment, ON TREATMENT, OFF TREATMENT, Adverse Event Current Assessment, II. INFECTIONS, Other Adverse Events, Comments

E2603 Adverse Event Form - (CTCAE v3) NCT00110019 Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E75AC780-DB8D-20A4-E034-0003BA3F9857

Adverse Event- Report SirTac NCT02936388 - Adverse Event- Report

- 03/12/2017 - 1 Formulário, 1 Grupo de itens, 16 Elementos de dados, 1 Idioma

Grupo de itens: Report Adverse Event

Study part: Adverse Event- Report. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Adverse Events- Treatment SirTac NCT02936388 - Adverse Events- Treatment

- 03/12/2017 - 1 Formulário, 1 Grupo de itens, 129 Elementos de dados, 1 Idioma

Grupo de itens: Therapy Adverse Events

Study part: Adverse Events- Treatment. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Ethanol-Free Clobetasol Propionate Foam vs Vehicle Foam in Chronic Hand Dermatitis NCT01323673 - Unscheduled Visit; Concomitant Medications; Concomitant Procedures; Adverse Events; General Comments; Subject's Post-Study Questionnaire

- 30/01/2019 - 1 Formulário, 12 Grupos de itens, 60 Elementos de dados, 1 Idioma

Grupos de itens: Unscheduled Visit, Concomitant Medications, Concomitant Procedures, Adverse Events, General Comments, Subject's Post-Study Questionnaire, 1 - Skin Medicines used in past, 2 - Rate Qualities of Foam, 3 - Rate the Foam, 4 - Compare Foam to Other Types of Skin Medicines, 5 - Likely to be compliant using various types of Medicines, 6 - What do you like or not like about the Foam?

Study ID: 115054 Clinical Study ID: 115054 Study Title: Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01323673 Sponsor: GlaxoSmithKline Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Vehicle / Placebo Trade Name: clobetasol propionate Study Indication: Dermatitis, Chronic

Safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw HBVHib 103812 & 104727 - 104727 (DTPW-HBV=HIB-MENAC-TT-016 BST 013 (15/24M)) - Concomitant Vaccination; Medication, Non- serious Adverse Events; Study Conclusion

- 22/01/2019 - 1 Formulário, 8 Grupos de itens, 39 Elementos de dados, 1 Idioma

Grupos de itens: Concomitant Vaccination, Concomitant Vaccination , Medication, Medication, Non- serious Adverse Event, Non- serious Adverse Event , Study Conclusion , Investigator's signature

Study ID:103812 & 104727 Clinical Study ID:103812 & 104727 Study Title: Study to assess safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw-HBV/Hib when administered at 15 to 18 months of age and of a dose of Mencevax ACWY vaccine. Patient Level Data:N/A Clinicaltrials.gov Identifier:N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine Trade Name: Tritanrix HepB/Hiberix Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw HBVHib 103812 & 104727 - 103812 (DTPW-HBV=HIB-MENAC-TT-014 BST:013&004 (15-18M)) - Medication; Non- Serious Adverse Events; Study Conclusion

- 22/01/2019 - 1 Formulário, 6 Grupos de itens, 34 Elementos de dados, 1 Idioma

Grupos de itens: Medication, Medication, Non- serious Adverse Event, Non- serious Adverse Event, Study Conclusion, Investigator's signature

Study ID:103812 & 104727 Clinical Study ID:103812 & 104727 Study Title: Study to assess safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw-HBV/Hib when administered at 15 to 18 months of age and of a dose of Mencevax ACWY vaccine. Patient Level Data:N/A Clinicaltrials.gov Identifier:N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine Trade Name: Tritanrix HepB/Hiberix Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw HBVHib 103812 & 104727 - Visit 1 103812 (DTPW-HBV=HIB-MENAC-TT-014 BST:013&004 (15-18/24M)) - General Medical History/ Physical Examination; Vaccine Administration; Unsolicited adverse events; Solicited Adverse Events - Local Symptoms; Soliced adverse events - General Symptoms

- 22/01/2019 - 1 Formulário, 7 Grupos de itens, 89 Elementos de dados, 1 Idioma

Grupos de itens: General medical history/ Physical examination, Diagnosis, Baseline Measurement of mid left thigh circumference, Vaccine administration, Unsolicited Adverse events, Solicited Adverse Events - Local Symptoms, Soliced Adverse Events - General Symptoms

Study ID:103812 & 104727 Clinical Study ID:103812 & 104727 Study Title: Study to assess safety and reactogenicity of booster dose of either an investigational vaccination regimen or DTPw-HBV/Hib when administered at 15 to 18 months of age and of a dose of Mencevax ACWY vaccine. Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine Trade Name: Tritanrix HepB/Hiberix Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Palavras-chave

Índice

Modelos de dados selecionados